文献速递乳腺癌

年轻乳腺癌家族史与对侧乳腺癌风险:WECARE研究更新

Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
PubMed 文献 · J Clin Oncol · 2018-04-05

WECARE研究更新了对侧乳腺癌(CBC)风险估计,纳入1521例CBC病例和2212例匹配的单侧乳腺癌对照,诊断时年龄<55岁。任何一级亲属患乳腺癌者10年CBC绝对风险为8.1%,亲属<40岁诊断或患CBC时风险更高,与BRCA1/2有害突变携带者相当;排除BRCA1/2、ATM、CHEK2*1100delC、PALB2有害突变后估计不变。

要点

  • 任何一级亲属乳腺癌史者10年CBC绝对风险8.1%。
  • 亲属<40岁诊断或患CBC时10年风险达13.5%–14.1%。
  • 排除已知有害突变后风险估计不变,家族史独立指引治疗与筛查。

核心结论

  • 乳腺癌家族史赋予高对侧乳腺癌风险,即使排除有害突变携带者仍成立。

研究设计与样本

  • 基于人群的病例对照研究,比较1521例CBC病例与2212例个体匹配的单侧乳腺癌对照。
  • 参与者首次浸润性乳腺癌诊断于1985–2008年,诊断时年龄<55岁。
  • 部分女性检测BRCA1/2、ATM、CHEK2*1100delC和PALB2有害突变。
  • 采用多变量条件logistic回归估计率比,结合SEER*Stat数据估计累积绝对风险。

主要发现

  • 任何一级亲属乳腺癌史者10年CBC绝对风险8.1%(95% CI 6.7%–9.8%)。
  • 亲属<40岁诊断时10年绝对风险13.5%(95% CI 8.8%–20.8%)。
  • 亲属患CBC时10年绝对风险14.1%(95% CI 9.5%–20.7%)。
  • BRCA1/2有害突变携带者10年绝对风险18.4%(95% CI 16.0%–21.3%)。
  • 排除BRCA1/2、ATM、CHEK2*1100delC和PALB2有害突变后风险估计不变;调整已知单核苷酸多态性不影响估计。

临床怎么用

  • 临床医生应使用详细家族史指导年轻乳腺癌患者的治疗和未来筛查决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The Women's Environmental Cancer and Radiation Epidemiology (WECARE) study demonstrated the importance of breast cancer family history on contralateral breast cancer (CBC) risk, even for noncarriers of deleterious BRCA1/2 mutations. With the completion of WECARE II, updated risk estimates are reported. Additional analyses that exclude women negative for deleterious mutations in ATM, CHEK2*1100delC, and PALB2 were performed. Patients and Methods The WECARE Study is a population-based case-control study that compared 1,521 CBC cases with 2,212 individually matched unilateral breast cancer (UBC) controls. Participants were younger than age 55 years when diagnosed with a first invasive breast cancer between 1985 and 2008. Women were interviewed about breast cancer risk factors, including family history. A subset of women was screened for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2. Rate ratios (RRs) were estimated using multivariable conditional logistic regression. Cumulative absolute risks (ARs) were estimated by combining RRs from the WECARE Study and population-based SEER*Stat cancer incidence data. Results Women with any first-degree relative with breast cancer had a 10-year AR of 8.1% for CBC (95% CI, 6.7% to 9.8%). Risks also were increased if the relative was diagnosed at an age younger than 40 years (10-year AR, 13.5%; 95% CI, 8.8% to 20.8%) or with CBC (10-year AR, 14.1%; 95% CI, 9.5% to 20.7%). These risks are comparable with those seen in BRCA1/2 deleterious mutation carriers (10-year AR, 18.4%; 95% CI, 16.0% to 21.3%). In the subset of women who tested negative for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2, estimates were unchanged. Adjustment for known breast cancer single-nucleotide polymorphisms did not affect estimates. Conclusion Breast cancer family history confers a high CBC risk, even after excluding women with deleterious mutations. Clinicians are urged to use detailed family histories to guide treatment and future screening decisions for young women with breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Reiner AS, Sisti J, John EM, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2018. PMID: 29620998. doi:10.1200/JCO.2017.77.3424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。